Kornimate/medical-research-clean huggingface dataset:
extended platelet parameters as a means to differentiate immune thrombocytopenia from hypo-proliferative thrombocytopenias.

Conditions: Immune Thrombocytopenia; Chemotherapy Induced Thrombocytopenia; Myelodysplasia; Aplastic Anaemia

Summary: to utilise extended platelet parameters in order to individuate immune thrombocytopenia (itp) from hypo-proliferative causes of thrombocytopenia. to develop the clinical potential of the extended platelet parameters as they pertain to distinguishing different causes of thrombocytopenia from one another. to test the hypothesis that mean platelet component (mpc) and mean platelet mass (mpm) might distinguish between thrombocytopenia related to bone marrow dysfunction and immune mediated destruction of platelets.

patient to be registered at the haematology-oncology department mount sinai roosevelt hospital. inclusion criteria are as follows: all individuals age 18yrs and above capable of rendering consent known itp confirmed by response to ivig, glucocorticoids, or winrho and exclusion of all other possible causes of thrombocytopenia confirmed aplastic anemia \[as assessed through bone marrow trephine biopsy\]. chemotherapy-induced thrombocytopenia assessed at time of predicted nadir.

Eligibility criteria:
inclusion criteria: * all individuals age 18yrs and above capable of rendering consent * known itp confirmed by response to intravenous immune globulin (ivig), glucocorticoids, or winrho and exclusion of all other possible causes of thrombocytopenia * confirmed aplastic anemia \[as assessed through bone marrow trephine biopsy\] * chemotherapy induced thrombocytopenia assessed at time of predicted nadir. exclusion criteria: * suspected multifactorial thrombocytopenias and thrombocytopenia due to hypersplenism * chronic active hepatitis * those infected with hiv * patients receiving concomitant radiotherapy * gravid females * congenital thrombocytopenias

Keywords: itp thrombocytopenia mean platelet mass mean platelet component
the effect of neuro linguistic programming on covid-19 fear in kidney transplant

Conditions: Kidney Transplant Patients

Summary: the study was conducted experimentally to evaluate the effect of neurolinguistic programming on covid-19 fear in kidney transplant patients.

the study was conducted experimentally (prospective randomized single-blind clinical trial model) to evaluate the effect of neurolinguistic programming (nlp) on fear of covid-19 in kidney transplant patients. the study was carried out between june 2021 and october 2021. personal information form and fear of covid-19 scale (fcv-19s) were used to collect data. the data obtained from the research were evaluated with spss 25. according to the calculation made using g\*power 3.1 software, the sample size was determined as 74 (each group 37) with an effect size of 0.80, a margin of error of 0co.05, a confidence level of 0.95, and a population representation of 0.95. simple random sampling method, one of the probability sampling methods, was used to determine the participants. single-group columns between 1 and 300 were created using the random integer generator method, which located in the numbers sub-heading of the random.org website for the participants who met the sample selection criteria. participants were randomly assigned to numbers 1 and 2, considering the numbers 1 and 2 in the column. the number of the experimental or control group was determined by drawing lots at the beginning of the research

Eligibility criteria:
inclusion criteria:patients who could communicate verbally, had no hearing problems, had a high or moderate fear of covid-19 (20 or more), and had not applied nlp before were included in the study. - exclusion criteria: patients who wanted to leave voluntarily at any stage after being included in the study, and who had to be hospitalized again for organ rejection or any other reason while the study was ongoing, were excluded from the study. -

Keywords: neuro linguistic programming fear of covid-19 kidney transplant patients nurse
safety and efficacy of obatoclax mesylate (gx15-070ms) in the treatment of myelofibrosis with myeloid metaplasia

Conditions: Myelofibrosis

Summary: defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. obatoclax is designed to restore apoptosis through inhibition of the bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells.

this is a multi-center, open-label, phase ii study of single-agent obatoclax administered in 2-week cycles as a 24-hour infusion every 2 weeks at a fixed dose of 60 mg to patients with myelofibrosis. infusions may be administered on an outpatient basis. no investigational or commercial agents or therapies other than those described in the protocol may be administered with the intent to treat the patient's malignancy. supportive care measures including those directed at controlling symptoms resulting from myelofibrosis (blood products, growth factor, hydroxyurea, etc.) are allowed.

Eligibility criteria:
inclusion criteria: * histologically confirmed myelofibrosis with myeloid metaplasia. * no limitations on allowable type and amount of prior therapy. * patients must have normal organ function. * must be willing to submit to blood sampling for planned pk and pd analyzes. * must have ability to understand and willingness to sign a written informed consent form. exclusion criteria: * no other agents or therapies administered with the intent to treat malignancy. * patients with prior exposure to obatoclax. * uncontrolled, intercurrent illness. * pregnant women and women who are breast feeding.
neuronal activation accuracy in closed-loop spinal cord stimulation

Conditions: Chronic Pain; Neuropathic Pain; Persistent Spinal Pain Syndrome Type 2

Summary: observational, prospective, single-center to assess neuronal activation accuracy and stimulation sensation in patients with closed-loop spinal cord stimulation therapy.

the study follow patients with chronic pain who received an evoketm spinal cord stimulator. the main aim of this study is to evaluate what influence different settings on nerve activation have and how this affects patients\&#39; sensation.

Eligibility criteria:
inclusion criteria: * subject is deemed a suitable candidate for scs trial and permanent implant and has been routinely scheduled to undergo an scs trial phase with the evoke scs system. * subject has a minimum of pain intensity of 5/10 on the numeric rating scale (nrs) at baseline * subject is ≥ 18 years old. * subject is not pregnant or nursing. * subject is willing and capable of giving informed consent. exclusion criteria: * subject currently has an active implantable device including pacemakers, spinal cord stimulator or intrathecal drug delivery system. * subject is incapable of understanding or responding to the study questionnaires. * subject is incapable of understanding or operating the patient programmer handset.
effects of two anti-hiv drug regimens on hiv transmission risk behavior among smart study participants

Conditions: HIV Infections

Summary: the purpose of this study is to compare the effects of two different anti-hiv drug regimens on hiv transmission risk behavior among smart study participants.

it is important to consider the role that hiv infected individuals play in ongoing hiv transmission. different anti-hiv treatment regimens may lead to variations in hiv transmission risk behavior among hiv infected individuals. hiv infected people with viral loads of less than 1,000 copies/ml are less likely to transmit hiv through heterosexual sex. however, condom use sometimes decreases after individuals start combination antiretroviral therapy (art); also, some studies have shown an increased rate in acquiring sexually transmitted infections (stis) following initiation of art, and those on art may transmit a drug-resistant strain of hiv. in the smart study, participants were randomly assigned to one of two treatment groups: * group 1 participants will follow a drug conservation (dc) regimen in which art will be stopped or deferred until cd4 cell count drops below 250 cells/mm3, will be initiated until cd4 cell count is at least 350 cells/mm3, and then will be followed by episodic art based on cd4 cell count. * group 2 participants will follow a viral suppression (vs) regimen in which art is continued to keep viral loads as low as possible, regardless of cd4 cell count. the purpose of this study is to compare how the dc and vs regimens affect hiv transmission risk behavior among smart study participants. at baseline, participants will complete a questionnaire about their sexual behavior during the previous 2 months. they will also undergo urine and blood collection for sti testing. these same procedures will occur at months 4 and 12, then every year thereafter for the first 4 years that a participant is in the parent study. participants and their physicians will be notified of sti testing results so that patients can be referred to appropriate care.

Eligibility criteria:
inclusion criteria: * coenrollment in the smart study * parent or guardian willing to provide informed consent, if applicable

Keywords: treatment experienced
patterns of glaucoma in glaucoma subspecialty clinics in egypt and india in the year 2018

Conditions: Determining Patterns of Glaucoma in Glaucoma Sub-specialty Clinics in Two Countries: Egypt and India

Summary: in this study, we are aiming to identify the patterns of glaucoma observed and treated at glaucoma subspecialty clinics of kasr al-aini hospital, cairo university in cairo, egypt and corresponding clinics in sadguru netra chikitsalaya post graduate institute of ophthalmology in mumbai, maharashtra, india during the year 2018. we are hoping that this study would provide an update on current statistics available on indian population as well as provide novel numbers on the prevalence of glaucoma and its patterns in one of the largest tertiary care hospitals in egypt. these results will then be compared to patterns observed in other epidemiological studies done in other countries.


Eligibility criteria:
inclusion criteria: * all patients referred to glaucoma sub-specialty clinics in the year 2018 in two centres: kasr al-aini hospital in cairo and sadguru netra chikitsalaya postgraduate institute of ophthalmology in india exclusion criteria: * patients younger than 18 years old. * patients with incomplete examination data

Keywords: patterns glaucoma egypt india 2018
convalescent plasma for patients with covid-19: a randomized, single blinded, parallel, controlled clinical study

Conditions: Coronavirus; Coronavirus Infection

Summary: convalescent plasma (cp) has been used in recent years as an empirical treatment strategy when there is no vaccine or treatment available for infectious diseases. in the latest viral epidemics, such as the ebola outbreak in west africa in 2014, the world health organization issued a document outlining a protocol for the use of whole blood or plasma collected from patients who have recovered from the ebola virus disease by transfusion to empirically treat local infectious outbreaks

the process is based on obtaining plasma from patients recovered from covid-19 in colombia, and through a donation of plasma from the recovered, the subsequent transfusion of this to patients infected with coronavirus disease (covid-19). our group has reviewed the scientific evidence regarding the application of convalescent plasma for emergency viral outbreaks and has recommended the following protocol

Eligibility criteria:
inclusion criteria:fulfilling all the following criteria 1. olerder than 18. 2. hospitalized participants with diagnosis of covid 19 by real time - polymerase chain reaction. 3. severe cases according to the official guideline "pneumonia diagnosis and treatment scheme for novel coronavirus infection (trial version 7)". 4. sequential organ failure assessment score (sofa) \< 6. 5. ability to understand and the willingness to sign a written informed consent document. exclusion criteria: 1. female subjects who are pregnant or breastfeeding. 2. patients with prior allergic reactions to transfusions. 3. critical ill patients in intensive care units with requierment of invasive mechanical venitlation. 4. patients with surgical procedures in the last 30 days. 5. patients with active treatment for cancer (radiotherapy or chemotherapy). 6. hiv diagnosed patients with viral failure (detectable viral load\> 1000 copies / ml persistent, two consecutive viral load measurements within a 3 month interval, with medication adherence between measurements after at least 6 months of starting a new regimen antiretrovirals). 7. demonstrated coinfection that explains the patient's symptoms 8. end-stage chronic kidney disease (glomerular filtration rate \<15 ml / min / 1.73 m2). 9. child pugh c stage liver cirrhosis. 10. high cardiac output diseases. 11. autoimmune diseases or immunoglobulin a nephropathy. 12. patients have any condition that in the judgement of the investigators would make the subject inappropriate for entry into this study.

Keywords: covid-19 coronavirus disease 2019
a dose finding study followed by a safety and efficacy study for patients with multiple myeloma or lymphoma

Conditions: Multiple Myeloma; NonHodgkin Lymphoma

Summary: the phase 1 portion of this study will determine the safety of tas4464 and the most appropriate dose for patients with multiple myeloma or lymphoma.

the trial was put on clinical hold prior to phase 2 due to cases of drug induced liver injury meeting the criteria for hy's law. background and rationale: • tas4464 is an investigational nedd8 activating enzyme (nae) inhibitor, a compound which may affect cancer cell growth and survival. thus, tas4464 may help in the treatment of cancer. phase 1: primary: * to investigate the safety and tolerability of tas4464 * to identify a tolerated dose of tas4464 secondary: * to investigate the preliminary efficacy of tas4464 * to investigate the pharmacokinetics (pk) and the pharmacogenomics (pgx) of tas4464 * to investigate the pharmacodynamics of tas4464

Eligibility criteria:
inclusion criteria: 1. provide written informed consent 2. women of child-bearing potential must have a negative pregnancy test multiple myeloma: confirmed diagnosis of multiple myeloma with measurable disease, having been treated with at least two prior lines of therapy. lymphoma: confirmed diagnosis of non-hodgkin lymphoma with measurable disease, having been treated with at least one anthracycline-based therapy, with relapse or progression since the last treatment received. exclusion criteria: 1. any of the following treatments, within the specified time frame, prior to the first dose of tas4464: 1. major surgery within 28 days 2. radiation/chemotherapy within 21 days 3. monoclonal antibodies within 28 days 4. corticosteroid administration \>20 mg/day of prednisone or equivalent within 14 days 5. proteasome inhibitors within 14 days 6. immunomodulatory agents within 7 days 7. stem cell transplant within 3 months 8. current immunosuppressive treatment for graft versus host disease 9. current use of an investigational agent 2. active graft versus host disease 3. known serious illness or medical condition 4. prior treatment with tas4464 or known hypersensitivity to any of its inactive ingredients or drugs similar in class 5. pregnant or breast-feeding female

Keywords: multiple myeloma relapsed/refractory lymphoma non-hodgkin lymphoma diffuse large b-cell lymphoma dlbcl mantle cell lymphoma mcl peripheral t-cell lymphoma ptcl tas4464 nedd8 nae inhibitor neoplasms hematologic diseases myeloma
management of anxiety in intensive care unit including olfactotherapy

Conditions: Anxiety

Summary: the ocean observational study is a pilot study. the aim is to validate the interest of the intervention of essential oils, relaxing music and dim light on the anxiety of patient who are in the intensive care unit.

the primary endpoint is a numeric scale varying from 0 (no anxiety) to 10 (anxiety maximum).

Eligibility criteria:
inclusion criteria: * hospitalized in one of the departments participating in the study * presenting moderate to high intensity anxiety (digital scale ≥ 5); exclusion criteria: * having already benefited from the "zen cart" * having taken an anxiolytic during the past 48 hours * patient (s) intubated and / or sedated * allergy or known intolerance to one of the essential oils used * respiratory allergies, asthma, or a history of seizures * unable to understand the information note (linguistic reason, or related to his medical condition) * pregnant or lactating woman.
transcutaneous mechanical nerve stimulation (tmns) by vibration in the treatment of incontinence

Conditions: Urinary Incontinence

Summary: during transcutaneous mechanical nerve stimulation in spinal cord injured men an increase in pressure was observed in the external urethral sphincter along with an increase in bladder capacity. in a subsequent study it was demonstrated that tmns in women could induce pressure increment of the external urethral sphincter. a pilot study have since shown that after 6 weeks of stimulation 24 out of 33 women suffering from urinary stress incontinence were able to contract their pelvic floor muscles and had become free of symptoms. another pilot study has shown promising effect on the overactive bladder syndrome. the present study aims to treat urinary incontinence and includes 3 groups of patients with 40 patients in each group: women suffering from urinary stress incontinence, women suffering from urge incontinence and men suffering from urinary incontinence after a prostatectomy. a medical vibrator is used and in each group the subjects will be randomized to active treatment or placebo treatment. in women the stimulation will be performed at the perineum every day for 6 weeks with an amplitude of 2 mm and a frequency of 100 hz. in men the vibration parameter/location will be determined by the results of a pressure profile study also included. results will be evaluated on the basis of questionnaires, micturition diaries and diaper tests. if we are able to demonstrate a significant reduction in the incontinence symptoms in the subjects we asses that vibration can be a way of reestablishing a normal function of the pelvic floor muscles and bladder function in incontinent patients.


Eligibility criteria:
inclusion criteria: * women suffering from stress incontinence * women suffering from overactive bladder syndrome * men who are still incontinent at a minimum of one year after a radical prostatectomy exclusion criteria: * pregnant and nursing women will not be included in the study

Keywords: stress incontinence urge incontinence overactive bladder syndrome vibration nerve stimulation
a phase 1 study of mp-424, peginterferon alfa 2b, and ribavirin in hepatitis c

Conditions: Hepatitis C

Summary: the purpose of this study is to assess the safety, pharmacokinetics, hcv rna kinetics, and other viral characteristics after administration of two arms of mp-424 in combination with peginterferon alfa 2b (peg-ifn-a-2b) and ribavirin (rbv) to patients with chronic hepatitis c.


Eligibility criteria:
inclusion criteria: * patients diagnosed with genotype 1b chronic hepatitis c exclusion criteria: * patients diagnosed with decompensated cirrhosis * patients diagnosed with positive hbs antigen in the test

Keywords: chronic hepatitis c protease inhibitor telaprevir
novaferon for covid-19 treatment trial (nctt-005)

Conditions: Covid19

Summary: a multicenter, randomized, double-blind, placebo-controlled trial for hospitalized moderate covid-19 patients


Eligibility criteria:
inclusion criteria: * written informed consent has been obtained from the participants with age of over 20 years at the time of signing the informed consent. * sars-cov-2 infection is diagnosed by the positive sars-cov-2 detection of rt-pcr tests within 72 hours before the start of administration of the investigational drug * less than 6 days from onset of covid-19 symptoms to starting the administration of the investigational drug. the symptoms are defined as one or more of the following: fever (37.5 ºc or higher), respiratory symptoms (cough, shortness of breath, chest pain, sore throat, running nose, nasal congestion, etc.), headache, malaise, abdominal pain, diarrhea, nausea, vomiting, loss of smell, loss of taste, or other covid-19 symptoms defined by investigators or physicians. * have at least one of the following findings. * oxygen saturation (spo2) measured by pulse oximeter is less than 96% and more than 93%. * chest x-ray or ct scan shows pneumonia findings suggestive of covid-19 infection * need hospitalization and covid-19-related medical care. * require no supplemental oxygen. * women (less than 12 months after the last menstrual period) who have a negative pregnancy test (urine hcg qualification) and agree to take oral contraceptives or use condom during study period. exclusion criteria: * history of hypersensitivity to interferon or novaferon or any excipients of interferon or novaferon. * having received other antiviral treatments (favipiravir, remdesivir, interferon, etc.). * ctcae grade 3 or higher liver dysfunction (alt / ast\> 5uln) or renal dysfunction (egfr \<30 ml / min / 1.73 m2). * active infections or other medical conditions that contraindicate inhalation therapy. * inappropriate for inclusion in the clinical trial as determined by investigators.

Keywords: antiviral sars-cov-2 covid19
remote exercise swedeheart study

Conditions: Myocardial Infarction

Summary: the overall aim of the study is to evaluate if remote video exercise-based cardiac rehabilitation (excr), offered as an alternative to centre-based excr, can increase participation in excr sessions post myocardial infarction (mi).

due to the covid-19 pandemic, this study will be performed in two steps: 1). national feasibility and safety study. 2). national multicenter registry-based cluster randomized crossover clinical trial (rrct). 1. in the feasibility study, patients will be offered remote excr at all participating sites until the peak of the pandemic has been achieved and care goes back to normal. the feasibility study will include patients until aug 2022. 2. cr centers (not patients) will be cluster randomized to either the intervention or control. patients at intervention centers will be offered remote excr, usual care centre-based excr, or a combination of both modes, as self-preferred choice. at control centers, patients will be offered usual care centre-based excr only. the duration of each time period for each center will be 15 months. long-term follow-up will be performed 1 year and 3 years after the index cardiac event.

Eligibility criteria:
inclusion criteria: * written informed consent * diagnosis of type 1 myocardial infarction (ami) * age 18-79 years at discharge from hospital exclusion criteria: * patients with incomplete coronary revascularization defined as at least one remaining hemodynamically significant stenosis * severe valve or structural heart disease * severe heart failure (nyha iii - iv) * serious arrythmias * inability to understand swedish * no internet access at home (only applicable for patients in the intervention group who wants to perform remote excr) * pathological exercise test indicating high risk for adverse events during excr * more than 6 months between discharge form hospital and screening * any other condition that may interfere with the possibility for the patient to comply with the study protocol

Keywords: exercise-based cardiac rehabilitation secondary prevention ehealth telerehabilitation physical fitness health-related quality of life cost-effectiveness